Business Context and Reporting Period
This Form 8-K is a current report filed by Ocuphire Pharma, Inc. (not Opus Genetics, Inc.) on January 31, 2022. The filing serves to disclose a Regulation FD event regarding the company's upcoming Virtual Investor R&D Day.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a disclosure of an event rather than a financial statement.
Material Changes
No material financial changes versus a prior period are reported in this filing. The primary event is the scheduled presentation of new clinical data.
Guidance, Outlook, and Management Commentary
- Event: The company held a Virtual Investor R&D Day on January 31, 2022.
- Content: Management presented new data and updates on two clinical programs: APX3330 and Nyxol.
- Disclosure Status: The presentation materials (Exhibit 99.1) are furnished but not deemed "filed" for purposes of the Securities Act or Exchange Act, except as expressly referenced.
Investor Verification Checklist
- Verify the specific clinical data points and trial results for APX3330 and Nyxol in the attached Exhibit 99.1 (Investor Presentation Materials).
- Confirm the company name is Ocuphire Pharma, Inc. (Ticker: OCUP), as the input metadata incorrectly referenced Opus Genetics.
- Review subsequent filings for any financial impact or strategic shifts resulting from the R&D Day updates.